VivoSeq
Other

T-Cell NHL (PTCL or CTCL)

1

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

T-cell NHL (PTCL or CTCL) is an early-stage landscape with 1 program across 1 company. The most active players are Kyowa Kirin, Inc..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kyowa Kirin, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

KK2223

Kyowa Kirin, Inc.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 1, Multicenter, Open-label, Non-randomized, Dose-escalation and Backfill Study of KK2223 in Participants With Relapsed or Refractory T-cell Non Hodgkin Lymphoma
Not yet recruiting·KKyowa Kirin, Inc.·Phase 1·NCT07192471·72 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)